Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 100 of 164 matching drugs for ERBB3 — including drugs targeting any of its 29 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
tucatinib ERBB3 Direct 3
disitamab vedotin, tucatinib ERBB3 Direct 1
tucatinib, trastuzumab, oxaliplatin, leucovorin, fluorouracil, capecitabine, pembrolizumab ERBB3 Direct 1
tucatinib, trastuzumab, ramucirumab, paclitaxel, tucatinib placebo, trastuzumab placebo ERBB3 Direct 1
vandetanib ERBB3 Direct yes 0
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
neo212 oral capsule, ipilimumab, pembrolizumab, nivolumab, regorafenib, carboplatin, paclitaxel, folfiri protocol, bevacizumab NTRK1 SSL via NTRK1 4
regorafenib, (stivarga, bay73-4506), nivolumab (opdivo) NTRK1 SSL via NTRK1 4
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB2 SSL via ERBB2 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib ERBB4 SSL via ERBB4 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib FYN SSL via FYN 3
adavosertib, afatinib, afatinib dimaleate, binimetinib, biopsy, biospecimen collection, capivasertib, computed tomography, copanlisib, copanlisib hydrochloride, crizotinib, cytology specimen collection procedure, dabrafenib, dabrafenib mesylate, dasatinib, defactinib, defactinib hydrochloride, echocardiography, erdafitinib, fexagratinib, ipatasertib, laboratory biomarker analysis, larotrectinib, larotrectinib sulfate, magnetic resonance imaging, multigated acquisition scan, nivolumab, osimertinib, palbociclib, pertuzumab, pi3k-beta inhibitor gsk2636771, radiologic examination, radionuclide imaging, relatlimab, sapanisertib, sunitinib malate, taselisib, trametinib, trastuzumab, trastuzumab emtansine, ulixertinib, vismodegib NTRK1 SSL via NTRK1 3
afatinib ERBB2 SSL via ERBB2 yes 3
afatinib ERBB4 SSL via ERBB4 yes 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB2 SSL via ERBB2 3
mrtx849, pembrolizumab, cetuximab, afatinib ERBB4 SSL via ERBB4 3
trastuzumab emtansine ERBB2 SSL via ERBB2 yes 3
tucatinib ERBB2 SSL via ERBB2 yes 3
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB2 SSL via ERBB2 2
alectinib, brigatinib, lorlatinib 100 mg, osimertinib, sotorasib, dabrafenib, trametinib, selpercatinib, pembrolizumab, cemiplimab, nivolumab, carboplatin, pemetrexed, paclitaxel ERBB4 SSL via ERBB4 2
bevacizumab, dasatinib, fluorouracil, leucovorin, leucovorin calcium, oxaliplatin, quality-of-life assessment FYN SSL via FYN 2
eft226, sotorasib, fulvestrant, abemaciclib, trastuzumab ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib ERBB2 SSL via ERBB2 2
entrectinib, entrectinib, alectinib, atezolizumab, ipatasertib, trastuzumab emtansine, idasanutlin, inavolisib, belvarafenib, pralsetinib, gdc-6036, camonsertib NTRK1 SSL via NTRK1 2
ioa-244, avelumab injection, pemetrexed, cisplatin, ruxolitinib TYK2 SSL via TYK2 2
lapatinib ERBB2 SSL via ERBB2 yes 2
radiotherapy targeted to the primary lesion, radiotherapy targeted to the metastatic lesions, anti-pd-1 monoclonal antibody, trastuzumab, chemotherapy, r0 total/subtotal gastrectomy with d2 lymphadenectomy, metastasectomy, local ablative therapies ERBB2 SSL via ERBB2 2
regorafenib NTRK1 SSL via NTRK1 2
regorafenib, laboratory biomarker analysis NTRK1 SSL via NTRK1 2
trastuzumab ERBB2 SSL via ERBB2 yes 2
trastuzumab, abt-806, bemarituzumab, ramucirumab, nivolumab, standard cytotherapy ERBB2 SSL via ERBB2 2
trastuzumab, tipifarnib ERBB2 SSL via ERBB2 2
2b3-101, trastuzumab, 2b3-101 60 mg/m2 every 4 weeks, 2b3-101 50 mg/m2 every 3 weeks ERBB2 SSL via ERBB2 1
5-fu, leucovorin, docetaxel, oxaliplatin (flot), trastuzumab, post-operative treatment trastuzumab mono therapy ERBB2 SSL via ERBB2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB2 SSL via ERBB2 1
afatinib, biopsy, biospecimen collection, computed tomography, echocardiography, magnetic resonance imaging, radionuclide imaging ERBB4 SSL via ERBB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB2 SSL via ERBB2 1
afatinib, dasatinib, palbociclib, everolimus, olaparib ERBB4 SSL via ERBB4 1
afatinib, dasatinib, palbociclib, everolimus, olaparib FYN SSL via FYN 1
afatinib, docetaxel, radiation therapy ERBB2 SSL via ERBB2 1
afatinib, docetaxel, radiation therapy ERBB4 SSL via ERBB4 1
afatinib, gefitinib ERBB2 SSL via ERBB2 1
afatinib, gefitinib ERBB4 SSL via ERBB4 1
afatinib, irinotecan ERBB2 SSL via ERBB2 1
afatinib, irinotecan ERBB4 SSL via ERBB4 1
atorvastatin, temozolomide, radiotherapy HMGCR SSL via HMGCR 1
bevacizumab, dasatinib, placebo FYN SSL via FYN 1
biopsy, biospecimen collection, computed tomography, larotrectinib, magnetic resonance imaging NTRK1 SSL via NTRK1 1
biopsy, biospecimen collection, echocardiography, pertuzumab, radiologic examination, trastuzumab ERBB2 SSL via ERBB2 1
capecitabine, medi4736 (durvalumab), trastuzumab, rucaparib, ramucirumab ERBB2 SSL via ERBB2 1
carboplatin, laboratory biomarker analysis, paclitaxel, quality-of-life assessment, radiation therapy, therapeutic conventional surgery, trastuzumab ERBB2 SSL via ERBB2 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin MYC SSL via MYC 1
ce-mark approved laa closure devices, acetylsalicylic acid, clopidogrel, dabigatran, rivaroxaban, apixaban, edoxaban, phenprocoumon, warfarin TP53 SSL via TP53 1
cetuximab, trastuzumab ERBB2 SSL via ERBB2 1
cisplatin, 5-fluorouracil or capecitabine, trastuzumab, pertuzumab, gastrectomy ERBB2 SSL via ERBB2 1
dasatinib, erlotinib hydrochloride, gemcitabine hydrochloride FYN SSL via FYN 1
dasatinib, gemcitabine hydrochloride, laboratory biomarker analysis, mutation analysis, nucleic acid sequencing, immunohistochemistry staining method FYN SSL via FYN 1
dasatinib, laboratory biomarker analysis, physiologic testing FYN SSL via FYN 1
dasatinib, mfolfox6 FYN SSL via FYN 1
dasatinib, pharmacological study FYN SSL via FYN 1
dasatinib, temozolomide, placebo, radiation therapy FYN SSL via FYN 1
db-1310, trastuzumab, osimertinib ERBB2 SSL via ERBB2 1
disitamab vedotin, tucatinib ERBB2 SSL via ERBB2 1
disulfiram, copper, alkylating agents ACY1 SSL via ACY1 1
docetaxel, leucovorin, fluorouracil, cisplatin, docetaxel, cisplatin, fluorouracil, neulasta, or neupogen, docetaxel, leukvorin, flurouracil, cisplatin, trastuzumab ERBB2 SSL via ERBB2 1
docetaxel, oxaliplatin, capecitabine, trastuzumab ERBB2 SSL via ERBB2 1
entrectinib NTRK1 SSL via NTRK1 yes 1
evorpacept (alx148), trastuzumab, ramucirumab, paclitaxel ERBB2 SSL via ERBB2 1
fluorouracil (5-fu), capecitabine, durvalumab, oxaliplatin, trastuzumab, trastuzumab deruxtecan, cisplatin, pembrolizumab, volrustomig, rilvegostomig ERBB2 SSL via ERBB2 1
gemcitabine, oxaliplatin, imatinib NTRK1 SSL via NTRK1 1
imatinib, irinotecan, carboplatin NTRK1 SSL via NTRK1 1
irinotecan, cisplatin, simvastatin HMGCR SSL via HMGCR 1
laboratory biomarker analysis, lapatinib, lapatinib ditosylate, pharmacological study, therapeutic conventional surgery ERBB2 SSL via ERBB2 1
lapatinib, chemoradiation, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo ERBB2 SSL via ERBB2 1
lapatinib, placebo, capecitabine, oxaliplatin ERBB2 SSL via ERBB2 1
lmb-100, tofacitinib, mesothelin expression TYK2 SSL via TYK2 1
lonsurf, oxaliplatin, panitumumab, bevacizumab, trastuzumab, nivolumab ERBB2 SSL via ERBB2 1
medical cannabis HMGCR SSL via HMGCR 1
mitapivat, mitapivat-matching placebo, mitapivat-matching placebo PKLR SSL via PKLR 1
nabiximols, temozolomide, nabiximols-matched placebo HMGCR SSL via HMGCR 1
nal-iri, oxaliplatin, 5-fu, trastuzumab, pembrolizumab, nivolumab ERBB2 SSL via ERBB2 1
oxaliplatin, leucovorin, 5 fluorouracil, trastuzumab, avelumab ERBB2 SSL via ERBB2 1
palbociclib, afatinib ERBB2 SSL via ERBB2 1
palbociclib, afatinib ERBB4 SSL via ERBB4 1
pazopanib, lapatinib ERBB2 SSL via ERBB2 1
pembrolizumab, placebo, cisplatin, 5-fu, oxaliplatin, capecitabine, s-1, trastuzumab ERBB2 SSL via ERBB2 1
pembrolizumab, trastuzumab, oxaliplatin, capecitabine ERBB2 SSL via ERBB2 1
regorafenib, lomustine NTRK1 SSL via NTRK1 1
regorafenib, nivolumab, capeox, folfox regimen NTRK1 SSL via NTRK1 1
regorafenib, nivolumab, docetaxel, paclitaxel, irinotecan, trifluridine/tipracil NTRK1 SSL via NTRK1 1
regorafenib, temozolomide NTRK1 SSL via NTRK1 1
rosuvastatin HMGCR SSL via HMGCR yes 1
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.